Stratos Wealth Partners LTD. boosted its stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) by 13.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,935 shares of the company's stock after acquiring an additional 2,865 shares during the period. Stratos Wealth Partners LTD. owned 0.15% of Global X Genomics & Biotechnology ETF worth $313,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Avidian Wealth Solutions LLC boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 6.8% during the 2nd quarter. Avidian Wealth Solutions LLC now owns 12,302 shares of the company's stock worth $150,000 after buying an additional 788 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Global X Genomics & Biotechnology ETF by 3.4% during the second quarter. Oppenheimer Asset Management Inc. now owns 46,389 shares of the company's stock worth $567,000 after purchasing an additional 1,515 shares during the period. Insight Advisors LLC PA raised its position in shares of Global X Genomics & Biotechnology ETF by 5.5% during the second quarter. Insight Advisors LLC PA now owns 31,675 shares of the company's stock worth $486,000 after purchasing an additional 1,655 shares during the period. McGuire Investment Group LLC raised its position in shares of Global X Genomics & Biotechnology ETF by 0.4% during the second quarter. McGuire Investment Group LLC now owns 525,886 shares of the company's stock worth $6,426,000 after purchasing an additional 1,900 shares during the period. Finally, HighTower Advisors LLC raised its position in shares of Global X Genomics & Biotechnology ETF by 3.6% during the first quarter. HighTower Advisors LLC now owns 62,395 shares of the company's stock worth $939,000 after purchasing an additional 2,140 shares during the period.
Get
Global X Genomics & Biotechnology ETF alerts:
Global X Genomics & Biotechnology ETF Stock Down 0.2 %
Shares of NASDAQ:GNOM opened at $12.79 on Friday. Global X Genomics & Biotechnology ETF has a twelve month low of $10.48 and a twelve month high of $18.59. The stock's 50 day moving average is $12.97 and its 200-day moving average is $13.41.
Global X Genomics & Biotechnology ETF Profile
(Get Rating)
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
Featured Articles
- Get a free copy of the StockNews.com research report on Global X Genomics & Biotechnology ETF (GNOM)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
Stratos Wealth Partners Ltd.根據其提交給美國證券交易委員會(美國證券交易委員會)的最新Form 13F檔案,在第三季度,其在Global X基因組學&生物技術ETF(美國證券交易委員會:GNOM-GET評級)的持股增加了13.0%。該基金持有24,935股該公司股票,在此期間又購買了2,865股。Stratos Wealth Partners Ltd.截至最近一個季度末,持有全球X基因組學和生物技術ETF 0.15%的股份,價值313,000美元。
其他一些機構投資者和對沖基金最近也調整了對該公司的持股。Avidian Wealth Solutions LLC在第二季度將其持有的Global X基因組和生物技術ETF的股票增加了6.8%。Avidian Wealth Solutions LLC現在擁有12,302股該公司股票,價值15萬美元,上個季度又購買了788股。奧本海默資產管理公司(Oppenheimer Asset Management Inc.)在第二季度將其在Global X基因組學和生物技術ETF的股票頭寸提高了3.4%。奧本海默資產管理公司(Oppenheimer Asset Management Inc.)在此期間又購買了1,515股,目前持有46,389股該公司股票,價值567,000美元。Insight Advisors LLC PA在第二季度將其在Global X基因組學和生物技術ETF股票中的頭寸提高了5.5%。Insight Advisors LLC PA現在擁有31,675股該公司的股票,價值486,000美元,在此期間又購買了1,655股。McGuire Investment Group LLC在第二季度將其在Global X基因組學和生物技術ETF的股票頭寸增加了0.4%。McGuire Investment Group LLC在此期間又購買了1900股,現在擁有525,886股該公司股票,價值6,426,000美元。最後,HighTower Advisors LLC在第一季度將其在Global X基因組學和生物技術ETF的股票頭寸提高了3.6%。HighTower Advisors LLC現在擁有62,395股該公司的股票,價值93.9萬美元,在此期間又購買了2,140股。
到達
全球X基因組和生物技術ETF警報:
全球X基因組和生物技術ETF股票下跌0.2%
上週五,納斯達克:GNOM的股價開盤報12.79美元。Global X基因組學和生物技術ETF的12個月低點為10.48美元,12個月高位為18.59美元。該股的50日移動均線切入位為12.97美元,200日移動均線切入位為13.41美元。
全球X基因組和生物技術ETF簡介
(獲取評級)
完整基因組公司是一家生命科學公司,已經開發了脫氧核糖核酸(DNA)測序平臺並將其商業化。其完整的基因組分析平臺(CGA)將其人類基因組測序技術與先進的資訊學和數據管理軟體以及端到端外包服務模式相結合,為其客戶提供可用於基於基因組的研究的數據。
專題文章
- 免費獲取StockNews.com關於Global X基因組和生物技術ETF(GNOM)的研究報告
- MarketBeat:回顧中的一週01/02-01/06
- 為什麼CrowdStrike的股價舉步維艱?
- 2023年四隻被低估的醫療保健股票
- WWE股票:文斯·麥克馬洪想要重返節目
- NVIDIA正在觸底,但現在還不能買入
獲得全球X基因組和生物技術ETF日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收關於Global X基因組學和生物技術ETF及相關公司的最新新聞和分析師評級的每日簡明摘要。